Anteris Technologies' milestone IPO

Anteris Technologies Global Corp. (ASX:AVR) has successfully completed its initial public offering in the United States, raising approximately US$88.8 million. The IPO included the sale of 14,800,000 shares at US$6.00 each. The company's shares began trading on Nasdaq on December 13, 2024, and the CDIs were listed on the ASX on December 17, 2024.

Anteris Technologies' strategic outlook

The successful IPO of Anteris Technologies Global Corp. marks a significant achievement, allowing the company to raise US$88.8 million, with the potential for an additional US$13.3 million if underwriters exercise their option to buy more shares. The proceeds will focus on the development of the DurAVR® THV, a balloon-expandable heart valve that uses ADAPT® tissue technology, known for its anti-calcification properties. This will include a pivotal global study for treating aortic stenosis. Anteris is positioned to enhance its innovative heart valve technology and further its strategic goals in advancing treatments for patients with severe aortic stenosis.

Executive insights on IPO success

The funds raised will primarily support the development of Anteris' lead product, the DurAVR® Transcatheter Heart Valve (THV), aimed at treating severe aortic stenosis. Additional proceeds will be used for a global pivotal study, working capital, and other general corporate purposes, including debt repayment.